Covaxin Phase 3 Trial Data Shows 77.8 Per Cent Efficacy Against Symptomatic COVID, Finds Study Published In Lancet
Hyderabad-based Bharat Biotech's Covaxin Covid-19 vaccine has demonstrated an efficacy of 77.8 per cent against symptomatic COVID-19 and is 93.4 per cent effective against severe symptomatic Covid-19 during the phase 3 trials, finds a study published in medical journal Lancet.
The Covaxin, also known as BBV152 vaccine, has been developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
"In the final per-protocol analysis, measured 14 days after the second of two doses of BBV152, we estimated a vaccine efficacy of 77.8% against symptomatic COVID-19 disease and, importantly, based on the limited data available, a higher efficacy against severe COVID-19 of 93.4%," said the study published on Thursday (11 November).
"This phase 3 study was done during a period that included the second wave of COVID-19 infections in India, with a peak of more than 400 000 new cases per day, when BBV152 was assessed against all ciruclating variants," it added.
Among 50 cases confirmed to be positive for the delta (B.1.617.2) variant, 13 were in the vaccine group and 37 were in the placebo group, resulting in a vaccine efficacy of 65.2 per cent, the study found.
Efficacy against the kappa (B.1.617.1) variant was 90·1 per cent, it added.
The study was conducted with participants from diverse geographical locations, enrolling 25,798 participants across 25 hospitals in India.
As you are no doubt aware, Swarajya is a media product that is directly dependent on support from its readers in the form of subscriptions. We do not have the muscle and backing of a large media conglomerate nor are we playing for the large advertisement sweep-stake.
Our business model is you and your subscription. And in challenging times like these, we need your support now more than ever.
We deliver over 10 - 15 high quality articles with expert insights and views. From 7AM in the morning to 10PM late night we operate to ensure you, the reader, get to see what is just right.
Becoming a Patron or a subscriber for as little as Rs 1200/year is the best way you can support our efforts.